Literature DB >> 16476815

The G93C mutation in superoxide dismutase 1: clinicopathologic phenotype and prognosis.

Luc Régal1, Ludo Vanopdenbosch, Petra Tilkin, Ludo Van den Bosch, Vincent Thijs, Rafael Sciot, Wim Robberecht.   

Abstract

BACKGROUND: Twenty percent of familial amyotrophic lateral sclerosis (ALS) is caused by mutations in the superoxide dismutase 1 gene (SOD1). Few data exist on their clinicopathologic phenotypes.
OBJECTIVES: To determine the clinical and pathologic phenotype associated with the G93C mutation in SOD1 and to compare survival in familial ALS related to this mutation with survival in other ALS subgroups.
DESIGN: Retrospective study.
SETTING: Tertiary referral center for neuromuscular disorders. PATIENTS: Twenty patients with the G93C mutation for whom clinical data were available and 1 patient with pathologic data. MAIN OUTCOME MEASURES: Characteristics and survival compared with other ALS subgroups, adjusting for known prognostic factors.
RESULTS: The G93C mutation was associated with a purely lower motor neuron phenotype without bulbar involvement. Presence of the mutation independently predicted longer survival compared with other ALS subgroups. Pathologic examination showed degeneration of the anterior horn, spinocerebellar tracts, and posterior funiculi, with minimal involvement of corticospinal tracts and no degeneration of brainstem motor nuclei. Survival motor neuron gene copy number had no significant influence on age at onset or survival in patients with the G93C mutation.
CONCLUSIONS: These findings add to the knowledge of SOD1-related familial ALS and demonstrate further clinicopathologic variability between different SOD1 mutations. Finally, they demonstrate the independent prognostic value of the G93C mutation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16476815     DOI: 10.1001/archneur.63.2.262

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  26 in total

1.  Presymptomatic activation of the PDGF-CC pathway accelerates onset of ALS neurodegeneration.

Authors:  Sebastian A Lewandowski; Ingrid Nilsson; Linda Fredriksson; Peter Lönnerberg; Lars Muhl; Manuel Zeitelhofer; Milena Z Adzemovic; Susanne Nichterwitz; Daniel A Lawrence; Eva Hedlund; Ulf Eriksson
Journal:  Acta Neuropathol       Date:  2015-12-19       Impact factor: 17.088

Review 2.  The phenotypic variability of amyotrophic lateral sclerosis.

Authors:  Bart Swinnen; Wim Robberecht
Journal:  Nat Rev Neurol       Date:  2014-10-14       Impact factor: 42.937

3.  Boosting the peripheral immune response in the skeletal muscles improved motor function in ALS transgenic mice.

Authors:  Maria Chiara Trolese; Carlotta Scarpa; Valentina Melfi; Paola Fabbrizio; Francesca Sironi; Martina Rossi; Caterina Bendotti; Giovanni Nardo
Journal:  Mol Ther       Date:  2022-04-27       Impact factor: 12.910

Review 4.  Management of amyotrophic lateral sclerosis.

Authors:  Philippe Corcia; Vincent Meininger
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 5.  The changing scene of amyotrophic lateral sclerosis.

Authors:  Wim Robberecht; Thomas Philips
Journal:  Nat Rev Neurosci       Date:  2013-03-06       Impact factor: 34.870

Review 6.  Fly for ALS: Drosophila modeling on the route to amyotrophic lateral sclerosis modifiers.

Authors:  Francesco Liguori; Susanna Amadio; Cinzia Volonté
Journal:  Cell Mol Life Sci       Date:  2021-07-28       Impact factor: 9.261

7.  Destabilizing protein polymorphisms in the genetic background direct phenotypic expression of mutant SOD1 toxicity.

Authors:  Tali Gidalevitz; Thomas Krupinski; Susana Garcia; Richard I Morimoto
Journal:  PLoS Genet       Date:  2009-03-06       Impact factor: 5.917

8.  Protein aggregation and protein instability govern familial amyotrophic lateral sclerosis patient survival.

Authors:  Qi Wang; Joshua L Johnson; Nathalie Y R Agar; Jeffrey N Agar
Journal:  PLoS Biol       Date:  2008-07-29       Impact factor: 8.029

9.  Genotype-phenotype relationship in hereditary amyotrophic lateral sclerosis.

Authors:  Satoshi Yamashita; Yukio Ando
Journal:  Transl Neurodegener       Date:  2015-07-24       Impact factor: 8.014

10.  Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis.

Authors:  Irene G Salado; Miriam Redondo; Murilo L Bello; Concepción Perez; Nicole F Liachko; Brian C Kraemer; Laetitia Miguel; Magalie Lecourtois; Carmen Gil; Ana Martinez; Daniel I Perez
Journal:  J Med Chem       Date:  2014-03-12       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.